Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ObsEva SA
  6. News
  7. Summary
    OBSV   CH0346177709

OBSEVA SA

(OBSV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Press Release : ObsEva Presents PROLONG Phase 2a -2-

06/10/2021 | 01:00am EDT
to, and does not intend to, update any forward-looking statements, 
whether as a result of new information, future events or otherwise. 
 
   For further information, please contact: 
 
   CEO Office contact 
 
   Shauna Dillon 
 
   Shauna.dillon@obseva.ch 
https://www.globenewswire.com/Tracker?data=xWc8a80gTeIfqA3uIRrg0_0iNIYI3NPY4yIHrQ1bMVaIuYHejmR5VT645Ul23eL6O4mRGh0PvG454ky1DAXJ0V5uw240H5g_Rv2Gt8Y5n9o= 
 
 
   +41 22 552 1550 
 
   Investor Contact: 
 
   Joyce Allaire 
 
   jallaire@lifesciadvisors.com 
https://www.globenewswire.com/Tracker?data=O045SHorQlFeyUQ_g2rPqaGKiBJsHHbLjXUqyh0GMOYq-9Ydomk9E0Xql2rz7IV5Pyr9YQEEx7srJM8f6fGNzxLXnwNyetnGh2W9uKx6yKM6EVkH0BmCRyrtpUVde-yt 
 
 
   +1 (617)-435-6602 
 
 
 
 
 
 
 
   Attachment 
 
 
   -- Press Release in Pdf 
      https://ml-eu.globenewswire.com/Resource/Download/65ad4d1b-371e-4b8b-8a06-99a11e0f4122 
 
 
 
 
 
 
 

(END) Dow Jones Newswires

June 10, 2021 01:00 ET (05:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL -1.58% 33290.08 Delayed Quote.10.51%
OBSEVA SA 0.34% 2.98 Delayed Quote.43.27%
All news about OBSEVA SA
06/10OBSEVA  : Proof-of-Concept Study Shows Potential of Ebopiprant Drug as Treatment..
MT
06/10OBSEVA  : Ebopiprant Therapy Shows Efficacy in Pregnant Women With Spontaneous P..
MT
06/10ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022)..
GL
06/10PRESS RELEASE  : ObsEva Presents PROLONG Phase 2a -2-
DJ
06/10PRESS RELEASE : ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopip..
DJ
06/02PRESS RELEASE : ObsEva Announces Oral Presentation at the RCOG Virtual World Con..
DJ
06/02ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021
GL
06/01OBSEVA  : Announces that Shareholders Approved all Board Proposals at its 2021 A..
PU
05/31PRESS RELEASE : ObsEva SA Announces that Shareholders Approved all Board Proposa..
DJ
05/31ObsEva SA Announces that Shareholders Approved all Board Proposals at its 202..
GL
More news
Financials (USD)
Sales 2021 0,01 M - -
Net income 2021 -79,3 M - -
Net cash 2021 30,7 M - -
P/E ratio 2021 -2,95x
Yield 2021 -
Capitalization 222 M 222 M -
EV / Sales 2021 19 104x
EV / Sales 2022 10,8x
Nbr of Employees 43
Free-Float 62,9%
Chart OBSEVA SA
Duration : Period :
ObsEva SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OBSEVA SA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 20,50 $
Last Close Price 2,98 $
Spread / Highest target 705%
Spread / Average Target 588%
Spread / Lowest Target 470%
EPS Revisions
Managers and Directors
NameTitle
Brian O'Callaghan Chief Executive Officer & Director
David Renas Chief Financial Officer
Frank A. G. M. Verwiel Chairman
Jean-Pierre Gotteland Chief Scientific Officer, Head-R&D
Elizabeth Ijeoma Onyemelukwe Garner Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
OBSEVA SA43.27%222
GILEAD SCIENCES, INC.14.33%83 541
WUXI APPTEC CO., LTD.24.70%63 775
REGENERON PHARMACEUTICALS11.35%55 705
BIONTECH SE160.57%51 304
VERTEX PHARMACEUTICALS-20.52%48 628